TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23933066

Group type: EXPERIMENTAL
Intervention: Strength and endurance training performed twice a week (SE2, n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Strength and endurance training performed three times per week (SE3, n=12)
Number of subjects: 24
Study: 20692104

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo TSST
Number of subjects: 40
Study: 19047288

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study: 16884320

Group type: EXPERIMENTAL
Intervention: Febuxostat 10-240 mg
Number of subjects: 120
Study: 15633321

Group type: EXPERIMENTAL
Intervention: 3% potassium oxalate gel
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 15
Study: 10564141

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (NP) infusion (0.3-1.0 microgram.kg(‐1).min(‐1))
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8638581

Group type: EXPERIMENTAL
Intervention: Treatment without extraction
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Extraction decisions
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Reasons for extraction
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Overall reasons for extraction
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Secondary considerations
Number of subjects: 148
Study: 1666275

Group type: EXPERIMENTAL
Intervention: Quadrantectomy
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Halsted radical mastectomy
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Patey radical mastectomy
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Madden radical mastectomy
Number of subjects: 848

Group type: COMPARATOR
Intervention: All surgical treatments
Number of subjects: 848
Study: 6339312

Group type: EXPERIMENTAL
Intervention: Furosemide (80 mg/day, increased to 160 mg/day if no response)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spironolactone (150 mg/day, increased to 300 mg/day if no response)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Spironolactone (after furosemide failure)
Number of subjects: 40
Study: 31415797

Group type: EXPERIMENTAL
Intervention: 4 Gy × 5
Number of subjects: 203

Group type: COMPARATOR
Intervention: 3 Gy × 10
Number of subjects: 203
Study: 28825423

Group type: EXPERIMENTAL
Intervention: DMXB-A 150 mg (extended-release formulation) administered four times daily for 1 month
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 80
Study: 27108818

Group type: EXPERIMENTAL
Intervention: Propofol (2mg/kg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Etomidate (0.3mg/kg)
Number of subjects: 100
Study: 23689047

Group type: EXPERIMENTAL
Intervention: Oxygen-driven nebulization (ODN) at 4-5 L/min
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oxygen-driven nebulization (ODN) at 6-7 L/min
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oxygen-driven nebulization (ODN) at 8-9 L/min
Number of subjects: 9
Study: 22300505

Group type: EXPERIMENTAL
Intervention: Brief nurse practitioner intervention (up to three home visits and two telephone calls)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Usual care (standard medical care including access to case management services)
Number of subjects: 199
Study: 21086650

Group type: EXPERIMENTAL
Intervention: Reamberin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucose-salt solutions
Number of subjects: 0
Study: 18515672

Group type: EXPERIMENTAL
Intervention: Doppler-derived peak diastolic gradient
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Doppler-derived mid diastolic gradient
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Doppler-derived end diastolic gradient
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Doppler pulmonary artery diastolic gradients
Number of subjects: 38
Study: 15842989

Group type: EXPERIMENTAL
Intervention: Gentle, seated exercise program
Number of subjects: 82

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 82
Study: 12848774

Group type: EXPERIMENTAL
Intervention: Retigabine 200 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Retigabine 200 mg every 8 h on day 32
Number of subjects: 15

Group type: COMPARATOR
Intervention: Phenobarbitone 90 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Phenobarbitone 90 mg after retigabine administration
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: AWD21‐360 (metabolite of retigabine)
Number of subjects: 15
Study: 10493336

Group type: EXPERIMENTAL
Intervention: 5-component acellular pertussis vaccine
Number of subjects: 366

Group type: COMPARATOR
Intervention: Whole cell pertussis vaccine
Number of subjects: 366
Study: 8902922

Group type: EXPERIMENTAL
Intervention: Vigabatrin (2 g daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1988239

Group type: EXPERIMENTAL
Intervention: Magnesium hydroxide (850 mg) with glipizide (5 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (water) with glipizide (5 mg)
Number of subjects: 8
Study: 6294732

Group type: EXPERIMENTAL
Intervention: Intramuscular sincalide
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Intravenous sincalide
Number of subjects: 35

Group type: COMPARATOR
Intervention: Intramuscular placebo
Number of subjects: 35
Study: 31864163

Group type: EXPERIMENTAL
Intervention: Pharmacotherapies (specific types not mentioned)
Number of subjects: 1051
Study: 30108163

Group type: EXPERIMENTAL
Intervention: Glutamine (5 g t.i.d.)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 28547078

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 adrenaline as buccal and lingual infiltration
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2% lignocaine with 1:80,000 adrenaline using classic direct inferior alveolar nerve block
Number of subjects: 100
Study: 26903288

Group type: EXPERIMENTAL
Intervention: Mild hypercapnia (PaCO2 45-55mmHg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Normocapnia (PaCO2 35-45mmHg)
Number of subjects: 7
Study: 23979151

Group type: EXPERIMENTAL
Intervention: Various antibiotics tested (excluding imipenem)
Number of subjects: 19756

Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 19756

Group type: COMPARATOR
Intervention: Geographic regions (North Europe)
Number of subjects: 19756

Group type: COMPARATOR
Intervention: Asia
Number of subjects: 19756
Study: 21789502

Group type: EXPERIMENTAL
Intervention: 512 Psychological Intervention Model (512 PIM)
Number of subjects: 2368

Group type: EXPERIMENTAL
Intervention: Debriefing
Number of subjects: 2368

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2368
Study: 19682170

Group type: EXPERIMENTAL
Intervention: Isoproterenol (ISO) administered in escalating doses of 5, 10, 15, and 20 microg/min
Number of subjects: 112

Group type: COMPARATOR
Intervention: Rapid atrial pacing (RAP)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Cardioversion for persistent AF after ablation
Number of subjects: 112
Study: 18845996

Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX) 60 mg/m² every 3 weeks
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 50 mg/m² every 4 weeks
Number of subjects: 509
Study: 12417546

Group type: EXPERIMENTAL
Intervention: Pulmonary veins (PVs) in patients with AF
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pacing in PVs in patients with AF
Number of subjects: 48

Group type: COMPARATOR
Intervention: Pulmonary veins (PVs) in control patients
Number of subjects: 48
Study: 10357241

Group type: EXPERIMENTAL
Intervention: Colloid osmotic pressures (COP's) in patients with bilateral ankle oedema
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colloid osmotic pressures (COP's) in healthy volunteers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colloid osmotic pressures (COP's) in treated hypertensives
Number of subjects: 0
Study: 8455319

Group type: EXPERIMENTAL
Intervention: Simultaneous infusion of all substrates with bolus‐based intermittent infusions during 60 minutes six times per day (24 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sequential infusion of fat plus amino acids at a constant rate over 12 hours during daytime followed by glucose infusion at a constant rate for 12 hours during nighttime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simultaneous infusion of all substrates at a constant rate over 24 hours
Number of subjects: 0
Study: 3510410

Group type: EXPERIMENTAL
Intervention: Dexamethasone (40 mg/m2 for doxorubicin, 95 mg/m2 for cis-platinum) administered intravenously 15 min prior to chemotherapy
Number of subjects: 27
Study: 29758154

Group type: EXPERIMENTAL
Intervention: Oscillating-rotating electric rechargeable toothbrush (Oral-B® PRO 1000, D16U)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sonic toothbrush (Philips Sonicare® Diamond Clean Toothbrush with AdaptiveClean brush head)
Number of subjects: 150
Study: 27179693

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (20-Hz) targeting the left temporoparietal cortex, 4 sessions over 2 days (total 10,400 stimulations)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 30
Study: 26058585

Group type: EXPERIMENTAL
Intervention: Low dose theophylline (Uniphyllin MR 200 mg tablets)
Number of subjects: 1424

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1424
Study: 23666275

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravenous meperidine
Number of subjects: 80
Study: 21228269

Group type: EXPERIMENTAL
Intervention: CD36 SNPs (rs1984112, rs1527479, rs7755, rs1527483) in SU.VI.MAX cohort
Number of subjects: 1614

Group type: EXPERIMENTAL
Intervention: CD36 SNPs (rs1984112, rs1761667, rs1527479) in HELENA Study
Number of subjects: 1614

Group type: EXPERIMENTAL
Intervention: Interaction with fasting serum triglycerides and long‐chain polyunsaturated fatty acids
Number of subjects: 1614
Study: 18155202

Group type: EXPERIMENTAL
Intervention: Pre-ART cycle screening with saline infusion sonohysterography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal endometrial lining
Number of subjects: 0
Study: 16580384

Group type: EXPERIMENTAL
Intervention: Intranasal E2/NET (175 microg/275 microg) as a spray
Number of subjects: 233

Group type: COMPARATOR
Intervention: Oral E2/NETA (1 mg/0.5 mg) as a capsule
Number of subjects: 233
Study: 12960704

Group type: EXPERIMENTAL
Intervention: Autogenic relaxation training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 50
Study: 10666351

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 9461

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9461
Study: 9586788

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Oral, semielemental diet (SED)
Number of subjects: 23
Study: 7921321

Group type: EXPERIMENTAL
Intervention: Telephone survey recruitment
Number of subjects: 357

Group type: COMPARATOR
Intervention: Community media campaign
Number of subjects: 357
Study: 3041336

Group type: EXPERIMENTAL
Intervention: Zilactin (hydroxypropyl cellulose film former)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Widely available topical preparation
Number of subjects: 32
Study: 31693197

Group type: EXPERIMENTAL
Intervention: Early repolarization (ER) pattern with Jp ≥2 mm
Number of subjects: 17901

Group type: EXPERIMENTAL
Intervention: Early repolarization (ER) pattern with Jp ≥2 mm in Hispanic patients
Number of subjects: 17901

Group type: COMPARATOR
Intervention: Early repolarization (ER) pattern with Jp ≥1 mm
Number of subjects: 17901
Study: 29843761

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture treatment for 10 days in addition to routine pharmacological treatment.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Routine pharmacological treatment alone (Control group).
Number of subjects: 150
Study: 28241354

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (n=60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (n=60)
Number of subjects: 120
Study: 26232375

Group type: EXPERIMENTAL
Intervention: Romosozumab (1 or 2 mg/kg Q2W or 2 or 3 mg/kg Q4W)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Romosozumab
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 24002601

Group type: EXPERIMENTAL
Intervention: Rituximab SC 1400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trastuzumab SC 600 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rituximab SC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trastuzumab SC
Number of subjects: 0
Study: 21917894

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (DRV/r) monotherapy
Number of subjects: 0
Study: 19274983

Group type: COMPARATOR
Intervention: Corticosteroids (prednisolone)
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: 3 month corticosteroid regimen
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: 5 month corticosteroid regimen
Number of subjects: 513

Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 513
Study: 17046383

Group type: COMPARATOR
Intervention: Local anesthesia (no additional medication)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Sublingual lorazepam (0.5 to 1 mg, approximately 20 min preoperatively)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Intravenous sedation (fentanyl and midazolam, doses from 50 to 125 microg of fentanyl and 1‐2 mg of midazolam)
Number of subjects: 330
Study: 12632336

Group type: EXPERIMENTAL
Intervention: Perfluorocarbon-induced lung growth (PILG)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV/control)
Number of subjects: 13
Study: 10955049

Group type: EXPERIMENTAL
Intervention: Specific prompting methods (either preference, food category, or visual)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Specific prompting for food category
Number of subjects: 96
Study: 8831520

Group type: EXPERIMENTAL
Intervention: Stapled closure
Number of subjects: 61

Group type: COMPARATOR
Intervention: Handsewn closure
Number of subjects: 61
Study: 1546818

Group type: EXPERIMENTAL
Intervention: Ketotifen (0.8 mg for <14 kg, 1.2 mg for ≥14 kg)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 121
Study: 3886404

Group type: EXPERIMENTAL
Intervention: Ranitidine + prazepam
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ranitidine + placebo
Number of subjects: 50
Study: 31517555

Group type: EXPERIMENTAL
Intervention: Kaempferia parviflora extract (KPE) - 5 tablets daily (150 mg KPFORCE™/tablet) for 4 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo - 5 tablets daily for 4 weeks
Number of subjects: 52
Study: 29851751

Group type: EXPERIMENTAL
Intervention: Pancrelipase (48,000 lipase units per meal)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Nonpancrelipase (control group)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Pancrelipase
Number of subjects: 88
Study: 27054302

Group type: EXPERIMENTAL
Intervention: Implementation intentions (if-then plans)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Implementation intentions (when-then plans)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (no plans formed)
Number of subjects: 168
Study: 25265548

Group type: EXPERIMENTAL
Intervention: Negative functional reappraisal
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Acceptance
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Negative dysfunctional reappraisal
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 99
Study: 22770916

Group type: EXPERIMENTAL
Intervention: NIPPV (4 cmH(2)O IPAP + 4 cmH(2)O PEEP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tidal Volume Breathing (TVB)
Number of subjects: 30
Study: 19918712

Group type: EXPERIMENTAL
Intervention: 0.5% Boswellic acid cream
Number of subjects: 15

Group type: COMPARATOR
Intervention: Base cream without Boswellic acid
Number of subjects: 15
Study: 17265548

Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Acupuncture plus moxibustion
Number of subjects: 39
Study: 16000173

Group type: EXPERIMENTAL
Intervention: Spinal endoscopic adhesiolysis
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (endoscopy into the sacral level without adhesiolysis, followed by injection of local anesthetic and steroid)
Number of subjects: 83
Study: 12140473

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using methyl 5‐aminolevulinate cream 160 mg/g, 3 hours application time, and red light (75 J/cm(2))
Number of subjects: 193

Group type: COMPARATOR
Intervention: Cryotherapy with liquid nitrogen spray
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using methyl 5‐aminolevulinate
Number of subjects: 193
Study: 10211540

Group type: EXPERIMENTAL
Intervention: Generic QOL measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disease-specific QOL measures
Number of subjects: 0
Study: 7675960

Group type: EXPERIMENTAL
Intervention: Buprenorphine (2, 4, and 8 mg sl.)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Methadone (15, 30, and 60 mg PO)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 2287640

Group type: EXPERIMENTAL
Intervention: Valproinat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diphenylhydantoin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primidon
Number of subjects: 0
Study: 88342

Group type: EXPERIMENTAL
Intervention: Late component of the contingent negative variation (CNV)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Early CNV
Number of subjects: 8
Study: 31884826

Group type: EXPERIMENTAL
Intervention: multi-phase intervention aimed at increasing social gaze behaviors
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: multi-phase intervention
Number of subjects: 5
Study: 26785097

Group type: EXPERIMENTAL
Intervention: Storz DCI® video laryngoscopy
Number of subjects: 93

Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: GlideScope Cobalt® video laryngoscopy
Number of subjects: 93
Study: 25567367

Group type: EXPERIMENTAL
Intervention: ABT-639 (up to 170 mg single dose and up to 160 mg BID multiple doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 24359267

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: General health, mental health, sleep quality, vitality
Number of subjects: 412
Study: 21493315

Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Electrocautery tonsillectomy
Number of subjects: 61
Study: 19660605

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 228

Group type: COMPARATOR
Intervention: Simvastatin 20 mg
Number of subjects: 228
Study: 16933268

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIG)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Anti-D immunoglobulin (anti-D)
Number of subjects: 37

Group type: COMPARATOR
Intervention: High-dose methyl prednisolone (HDMP)
Number of subjects: 37
Study: 15270996

Group type: EXPERIMENTAL
Intervention: Fast negative evaluations
Number of subjects: 346

Group type: COMPARATOR
Intervention: Slow negative evaluations
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Task performance
Number of subjects: 346
Study: 11270019

Group type: EXPERIMENTAL
Intervention: Remifentanil (1 microgram kg‐1 bolus followed by 0.1 microgram kg‐1 min‐1 infusion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sufentanil (0.1 microgram kg‐1 bolus over 60 s followed by 0.01 microgram kg‐1 min‐1 infusion)
Number of subjects: 30
Study: 9059867

Group type: EXPERIMENTAL
Intervention: p53 immunostaining
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: DNA-ploidy analysis
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combined p53 and DNA analysis
Number of subjects: 33
Study: 8454379

Group type: EXPERIMENTAL
Intervention: Flosequinan
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 3810050

Group type: EXPERIMENTAL
Intervention: Pivampicillin/pivmecillinam (PAPM) 450 mg and 900 mg every 12 h until catheter removal (max 1 week)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Pivampicillin/pivmecillinam (PAPM)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Cefotaxime (CFT) 1 g daily parenterally
Number of subjects: 261

Group type: COMPARATOR
Intervention: Cefotaxime (CFT)
Number of subjects: 261
Study: 29893193

Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 23

Group type: COMPARATOR
Intervention: Foam rolling
Number of subjects: 23
Study: 30376893

Group type: EXPERIMENTAL
Intervention: TXA dose A (15 mg/kg bolus dose over 20 min, followed by 2 mg/kg/hr infusion over 8 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TXA dose B (30 mg/kg bolus dose over 20 min, followed by 4 mg/kg/hr infusion over 8 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TXA dose A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TXA dose B
Number of subjects: 0
Study: 26942364

Group type: EXPERIMENTAL
Intervention: Vaginal swab test
Number of subjects: 140

Group type: COMPARATOR
Intervention: Urethral Q-tip test
Number of subjects: 140
Study: 24705965

Group type: EXPERIMENTAL
Intervention: Epidural
Number of subjects: 1785

Group type: COMPARATOR
Intervention: No Epidural
Number of subjects: 1785
Study: 23112824

Group type: EXPERIMENTAL
Intervention: Fasting during Ramadan
Number of subjects: 102
Study: 20520555

Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Colloid infusions (HES and human albumin)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Colloids (HES and human albumin)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Human albumin
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Succinylated gelatin and HES
Number of subjects: 200

Group type: COMPARATOR
Intervention: Colloids vs. lactated Ringer's solution
Number of subjects: 200